Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Monte Rosa Therapeutics is a biopharmaceutical company focused on discovering and developing precision medicines through a novel class of small molecules called molecular glue degraders (MGDs). Their proprietary QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) drug discovery platform enables the rational design and development of MGDs that can selectively degrade disease-causing proteins previously considered undruggable. The company's pipeline targets a range of indications, primarily in oncology and autoimmune/inflammatory diseases, with the goal of transforming patient outcomes.
The Boston headquarters serves as the central hub for corporate operations, research and development leadership, clinical development, and strategic decision-making.
Located in a modern life sciences facility within Boston's innovation-rich Seaport District, likely equipped with state-of-the-art laboratories and collaborative office spaces designed to foster scientific discovery.
The work culture is expected to be dynamic, science-driven, and highly collaborative, characteristic of an innovative biotech company. There's a strong emphasis on cutting-edge research, teamwork, and a shared mission to develop transformative therapies for patients.
Boston's Seaport, along with nearby Kendall Square, offers unparalleled access to a dense ecosystem of academic institutions, research organizations, skilled talent, venture capital, and potential collaborators, which is crucial for a company at the forefront of drug discovery.
Monte Rosa Therapeutics operates primarily from its headquarters in Boston, USA, and a significant research facility in Schlieren, Switzerland. This dual presence allows the company to engage with key scientific and biotech hubs in both North America and Europe. Its global functions support comprehensive drug discovery, preclinical development, and planning for international clinical trials and potential future commercialization of its novel molecular glue degraders.
645 Summer Street, Suite 102
Boston
MA
USA
Address: Monte Rosa Therapeutics AG, Technologiepark, Wagistrasse 27, CH-8952 Schlieren
The Schlieren office enables Monte Rosa to tap into European scientific talent, foster international collaborations, and support its global drug discovery and early development efforts.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Monte Rosa Therapeutics' leadership includes:
Monte Rosa Therapeutics has been backed by several prominent investors over the years, including:
Over the past 12 months, Monte Rosa Therapeutics has made significant additions to its executive team, appointing a new Chief Scientific Officer, Chief Operating Officer, and Chief Business Officer, while its former Chief Scientific Officer transitioned out of the company. These changes aim to strengthen leadership as the company advances its pipeline.
Discover the tools Monte Rosa Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Monte Rosa Therapeutics commonly uses the email format of the employee's first initial followed by their last name @monterosatx.com. Other variations might exist but this is the most prevalent pattern.
flast@monterosatx.com
Format
jdoe@monterosatx.com
Example
90%
Success rate
GlobeNewswire • May 9, 2024
Monte Rosa announced its Q1 2024 financial results, detailing progress with its lead clinical candidate MRT-2359 for MYC-driven tumors and discovery programs. The company confirmed its cash runway is expected to extend into the second half of 2026....more
GlobeNewswire • April 8, 2024
The company presented compelling preclinical findings for MRT-6160, a VAV1-targeting molecular glue degrader, at the American Association for Cancer Research (AACR) Annual Meeting, highlighting its potential for treating autoimmune diseases through selective VAV1 degradation....more
GlobeNewswire • January 2, 2024
Monte Rosa Therapeutics announced the appointment of Silvia Buonamici, Ph.D., as its new Chief Scientific Officer, bringing deep expertise in oncology drug discovery and development to lead the company's research initiatives....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Monte Rosa Therapeutics, are just a search away.